Human Oncology & Pathogenesis Program
The Jedd Wolchok Lab
Research
The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.
Some of our ongoing projects include:
- Investigation of the GITR pathway as it relates to regulatory and effector T cells.
- Use of OX40 agonists alone and in combination with chemotherapy.
- Exploration of the role of myeloid derived suppressor cells in tumor immunity.
- Studying of the mechanisms underlying coordinated regulation of myeloid cells and IDO in the tumor environment and their therapeutic relevance.
- Role of CD47 in T cell signaling.
- Developing optimal cancer vaccine strategies in pre-clinical mouse models.
- Role of exercise in immune checkpoint blockade.
We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.
Featured News
Publications
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol 2021:Jco2102229.
Budhu, S, Giese r, Gupta A, Fitzgerald K, Zappasodi, R, Schad S, Hirschhorn D, Campesato LF, DeHenau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, Merghoub T. Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Rep. 2021 Jan 12;34(2):108620.
Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T. Tim-4(+) cavity-resident macrophages impair anti-tumor CD8(+) T cell immunity. Cancer Cell 2021. May 29:S1535-6108(21)00272-5.
Zappasodi R, Serganova I, Cohen I, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, Lubin M, Ko M, Mane MM, Zhong H, Liu C, Ghosh A, Abu- Akeel M, Ackerstaff E, Koutcher JA, Ho PC, Delgoffe GM, Blasberg R, Wolchok JD and Merghoub T. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors. Nature 2021 Mar;591(7851):652-658.
Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight 2021;6.
People
Jedd D. Wolchok, MD, PhD, FASCO
Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program
- Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.
- Princeton University, Princeton, NJ BA
- New York University, New York, NY MS
- New York University, New York, NY PhD
- New York University, New York, NY MD
- View physician profile
- Physician profile
Members
- PhD in Immunology, McGill University, Montréal, Canada
- 646-888-2120
- Office Phone
- 646-888-2581
- Lab Phone
- 646-888-2120
- Office Phone
- 646-888-2585
- Lab Phone
- PhD in Biochemistry, University of São Paulo (USP), Brazil
- Universite Paris VI
- Universite Paris XI
- 646-888-2322
- Lab Phone
Lab Alumni
Lab Affiliations
Achievements
- The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)
Get in Touch
-
Clinical Office
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jedd D. Wolchok discloses the following relationships and financial interests:
-
Amgen
Provision of Services (uncompensated) -
Apricity Health
Ownership / Equity Interests; Provision of Services -
Arsenal IO Canada Parent, Inc.
Ownership / Equity Interests; Provision of Services -
Ascentage Pharma
Ownership / Equity Interests; Provision of Services -
Astellas
Provision of Services (uncompensated) -
AstraZeneca
Provision of Services (uncompensated) -
BeiGene, Ltd.
Ownership / Equity Interests; Provision of Services -
Bicara Therapeutics, Inc.
Provision of Services -
Boehringer Ingelheim
Provision of Services (uncompensated) -
Bristol-Myers Squibb
Provision of Services -
Chugai Pharmaceuticals
Provision of Services (uncompensated) -
Daiichi Sankyo
Provision of Services -
Dragonfly Therapeutics, Inc.
Provision of Services (uncompensated) -
Georgiamune, LLC
Provision of Services (uncompensated) -
Idera Pharmaceuticals, Inc.
Provision of Services (uncompensated)
-
Imvaq Therapeutics
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services -
Journal of Experimental Medicine
Provision of Services -
Linnaeus Therapeutics
Ownership / Equity Interests -
Maverick Therapeutics, Inc.
Provision of Services -
Merck & Co Inc.
Intellectual Property Rights; Provision of Services (uncompensated) -
Merial Limited
Intellectual Property Rights -
PsiOxus Therapeutics Ltd
Provision of Services (uncompensated) -
Recepta Biopharma S.A.
Provision of Services (uncompensated) -
Sellas Life Science Group
Provision of Services -
Surface Oncology
Provision of Services -
Tizona Therapeutics
Ownership / Equity Interests; Provision of Services -
Trieza Pharmaceuticals, Inc.
Ownership / Equity Interests -
Trishula Therapeutics, Inc.
Provision of Services -
Werewolf Therapeutics, Inc.
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.